Daten zu BAY 59-7939 auf dem XXth Kongress der International Society on Thrombosis & Haemostasis (ISTH)

6. - 12. August 2005 in Sydney, Australien


8. August 2005 ab 14:00 Uhr MESZ (12:00 Uhr GMT):
IR Telefonkonferenz - ISTH Review 2005

Die Audio-Aufzeichnung dieser Veranstaltung ist nicht mehr verfügbar.

Hintergrundinformationen (nur in Englisch verfügbar)
Thromboembolic disorders: A major cause of morbidity and mortalityDownload (PDF, 248 KB) sammeln
Current anticoagulant therapiesDownload (PDF, 241 KB) sammeln
Coagulation PathwayDownload (PDF, 81 KB) sammeln
GlossarDownload (PDF, 103 KB) sammeln

ISTH 2005 Abstracts zu BAY 59-7939

An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – For Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Dose-ranging Study

Prevention Of Venous Thromboembolism With An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – In Elective Hip Replacement: A Dose-Ranging Study

Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor

Interaction Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – With Antiplatelet Agents: Monitoring And Therapeutic Applications

Effect Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – on Clot-Bound Factor Xa Activity In Vitro

Effect of Enoxaparin on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct, Factor Xa Inhibitor

The Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – Inhibits Thrombin Generation In Vitro After Tissue Factor Pathway Activation

Antithrombotic Mechanism of Action of BAY 59-7939 – a Novel, Oral, Direct Factor Xa Inhibitor

Comparison of the Anticoagulant Properties of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor – with Fondaparinux and Enoxaparin

Letzte Änderung: 13. Januar 2014 Copyright © Bayer AG